Thus, these vaccines demonstrated the ability to elicit AR-specific and AR-V7-specific T cells responses in mice, which varied based on their genetic background and MHC-I repertoire, suggesting their potential utility against prostate cancer. The gene discussed is AR; the disease is Familial prostate cancer.